Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy

被引:22
作者
Ceia, F
Fonseca, C
Mota, T
Morais, H
Matias, F
Costa, C
Oliveira, AG
机构
[1] Univ Nova Lisboa, Sch Med Sci, Dept Med Therapeut, Lisbon, Portugal
[2] Hosp S Francisco Xavier, Med Serv, P-1400 Lisbon, Portugal
[3] Univ Nova Lisboa, Sch Med Sci, Dept Internal Med, Lisbon, Portugal
[4] Univ Nova Lisboa, Sch Med Sci, Dept Cardiol, Lisbon, Portugal
[5] Hosp Pulido Valente, Serv Cardiol, P-1750 Lisbon, Portugal
[6] EPICA, Grp Invest, P-1050 Lisbon, Portugal
[7] Datamed Ltd, Lisbon, Portugal
[8] Datamed, P-1200 Lisbon, Portugal
关键词
heart failure; primary care; guidelines; treatment;
D O I
10.1016/j.ejheart.2004.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic heart failure (CHF) is common and is frequently managed by primary care physicians (PCPs). Despite the European Society of Cardiology (ESC) Guidelines, standard treatments for CHF are frequently underutilised, particularly in primary care. Aim: To evaluate current drug therapy for CHF in adults with HF diagnosed according to ESC guidelines in the context of the EPICA study. Aetiological features and therapy relevant comorbidities were also analysed. Methods: EPICA was a community-based epidemiological study conducted in mainland Portugal. The study involved 365 primary care physicians, who evaluated 6300 primary care attendees aged over 25 years. CHIF was diagnosed by clinical and echocardiography criteria according to ESC guidelines. Results: Total of 551 cases of CHF were identified, with a mean age of 65 +/- 9 years. The estimated overall prevalence of CHF in the Portuguese population was 4.4%; 1.3% with and 1.7% without left ventricular systolic dysfunction (LVSD). There are 6,280,792 people aged > 25 years in Portugal, which extrapolates to 261,400 cases of heart failure. About 80% of patients had a history of hypertension, 39% had a history of coronary artery disease and 15% had atrial fibrillation. Only 58% of patients were on angiotensin-converting enzyme (ACE) inhibitors and 7% on beta-blockers. The type of ventricular dysfunction, age and presence of renal failure had little effect on prescription rates. Diuretics were prescribed in 78%. Thiazides were used more frequently in those with preserved systolic function and frusemide in those with left ventricular systolic dysfunction. Digoxin was prescribed more often to patients with than without left ventricular systolic dysfunction (34% vs. 17%; p = 0.02). Long-acting nitrates were prescribed to 20% and amiodarone to 8% of patients. Conclusion: The EPICA study, as in other studies in primary care in Europe, particularly the IMPROVEMENT study, suggests that greater efforts are required to improve training of primary care teams in the management of CHF. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:801 / 806
页数:6
相关论文
共 50 条
  • [31] Echocardiography-based qualification and response assessment to cardiac resynchronisation therapy in patients with chronic heart failure. The matrix metalloproteinase-9 substudy
    Szulik, Mariola
    Stabryla-Deska, Joanna
    Boidol, Joanna
    Lenarczyk, Radoslaw
    Kalarus, Zbigniew
    Kukulski, Tonnasz
    KARDIOLOGIA POLSKA, 2011, 69 (10) : 1043 - 1051
  • [32] Drug Treatment for Chronic Systolic Heart Failure
    Moerike, K.
    Sindermann, J. R.
    THORACIC AND CARDIOVASCULAR SURGEON, 2010, 58 : S170 - S172
  • [33] Drug Treatment of Chronic Heart Failure in the Elderly
    Gregor Leibundgut
    Matthias Pfisterer
    Hans-Peter Brunner-La Rocca
    Drugs & Aging, 2007, 24 : 991 - 1006
  • [34] Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
    Maltes, Sergio
    Cunha, Goncalo J. L.
    Rocha, Bruno M. L.
    Presume, Joao
    Guerreiro, Renato
    Henriques, Celia
    Rodrigues, Catarina
    Araujo, Ines
    Fonseca, Candida
    CARDIOLOGY, 2021, 146 (02) : 201 - 206
  • [35] Real-world clinical burden among patients with and without heart failure worsening after cardiac resynchronization therapy
    Chung, Eugene S.
    Rickard, John
    Lu, Xiaoxiao
    DerSarkissian, Maral
    Zichlin, Miriam L.
    Cheung, Hoi Ching
    Swartz, Natalia
    Greatsinger, Alexandra
    Duh, Mei S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (09) : 1489 - 1498
  • [36] "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
    Simpson, Joanne
    Benson, L.
    Jhund, P. S.
    Dahlstrom, U.
    McMurray, J. J. V.
    Lund, L. H.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (03) : 315 - 322
  • [37] Drug therapy in elderly heart failure patients
    Jankowska, Ewa A.
    Vitale, Cristiana
    Uchmanowicz, Izabella
    Tkaczyszyn, Michal
    Drozd, Marcin
    Ponikowski, Piotr
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0L) : L8 - L11
  • [38] Differences in drug treatment of chronic heart failure between European countries
    van Veldhuisen, DJ
    Charlesworth, A
    Crijns, HJGM
    Lie, KI
    Hampton, JR
    EUROPEAN HEART JOURNAL, 1999, 20 (09) : 666 - 672
  • [39] New Targets in Heart Failure Drug Therapy
    Correale, Michele
    Tricarico, Lucia
    Fortunato, Martino
    Mazzeo, Pietro
    Nodari, Savina
    Di Biase, Matteo
    Brunetti, Natale Daniele
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [40] Missed Opportunities in Identifying Cardiomyopathy Aetiology Prior to Advanced Heart Failure Therapy
    Aiad, Norman
    Elnabawai, Youssef A.
    Li, Boyangzi
    Narula, Navneet
    Gidea, Claudia
    Katz, Stuart D.
    Rao, Shaline D.
    Reyentovich, Alex
    Saraon, Tajinderpal
    Smith, Deane
    Moazami, Nader
    Pan, Stephen
    HEART LUNG AND CIRCULATION, 2022, 31 (06) : 815 - 821